UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Medline ® Abstracts for References 45,46

of 'Treatment of community-acquired pneumonia in adults who require hospitalization'

45
TI
Does empirical therapy with a fluoroquinolone or the combination of aβ-lactam plus a macrolide result in better outcomes for patients admitted to the general ward?
AU
Ruhe J, Mildvan D
SO
Infect Dis Clin North Am. 2013 Mar;27(1):115-32. Epub 2012 Dec 1.
 
Community-acquired pneumonia (CAP) is a frequent cause of morbidity and mortality in the United States and worldwide, in particular among older patients and those with significant comorbid conditions. Current guidelines recommend therapy with a fluoroquinolone or aβ-lactam plus a macrolide for the treatment of hospitalized adults with CAP who do not require admission to an intensive care unit. This article provides a brief summary and overview of the existing literature on this topic categorized by the main results; the potential implications for future clinical practice and research are discussed.
AD
Division of Infectious Diseases, Beth Israel Medical Center, Albert Einstein College of Medicine, New York, NY 10003, USA. jruhe@chpnet.org
PMID
46
 
 
http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm (Accessed September 2, 2010).
 
no abstract available